Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 9/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548751 | 0.91 | CACNA1H (0.59) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2544847 | 0.86 | CACNA1H (0.57) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13815482 | 0.80 | HTR2B (0.48) | CACNA1HCACNA1CHTR2B | |
| SCHEMBL13815483 | 0.80 | HTR2B (0.48) | CACNA1HCACNA1CHTR2B | |
| SCHEMBL2548684 | 0.76 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2543157 | 0.76 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2546630 | 0.76 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28562199 | 0.73 | POLB (0.52) | HTR2BPOLBMAPTHSD17B10TACR2 | |
| SCHEMBL2548193 | 0.72 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13815510 | 0.71 | POLB (0.46) | CACNA1HCACNA1CCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | claimed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | CACNA1H 5/4885CACNA1C 13/4885CYP3A4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.